Bladder Cancer News

Transforming Bladder Cancer Treatment: The Rise of Immunotherapy in Community Oncology Practices - Pharmaceutical Commerce

Transforming Bladder Cancer Treatment: The Rise of Immunotherapy in Community Oncology Practices Pharmaceutical Commerce

Sara Coca Membribes: New Therapeutic Options in Bladder Cancer - Oncodaily

Sara Coca Membribes: New Therapeutic Options in Bladder Cancer Oncodaily

Early Phase Evaluation of Intravesical Erdafitinib in NMIBC - Targeted Oncology

Early Phase Evaluation of Intravesical Erdafitinib in NMIBC Targeted Oncology

Bicycle to lay off 30% of staff, pivot away from Padcev challenger - BioPharma Dive

Bicycle to lay off 30% of staff, pivot away from Padcev challenger BioPharma Dive

EAU 2026: Treatment of High-grade NMIBC: Results from the VERSUS Study - UroToday

EAU 2026: Treatment of High-grade NMIBC: Results from the VERSUS Study UroToday

Metastatic Clear Cell Renal Cell Carcinoma Masquerading as Urinary Bladder Tumor: A Report of a Rare Case - Cureus

Metastatic Clear Cell Renal Cell Carcinoma Masquerading as Urinary Bladder Tumor: A Report of a Rare Case Cureus

J&J reports positive data for Erda-iDRS in bladder cancer - Clinical Trials Arena

J&J reports positive data for Erda-iDRS in bladder cancer Clinical Trials Arena

Bicycle finally falls | ApexOnco - Clinical Trials news and analysis - Oncology Pipeline

Bicycle finally falls | ApexOnco - Clinical Trials news and analysis Oncology Pipeline

Nogapendekin Alfa Inbakicept Joins NCCN Guidelines for Papillary-Only, BCG-Unresponsive NMIBC - OncLive

Nogapendekin Alfa Inbakicept Joins NCCN Guidelines for Papillary-Only, BCG-Unresponsive NMIBC OncLive

ImmunityBio Stock Jumps As New Bladder Cancer Guideline Boosts Anktiva Use - Benzinga

ImmunityBio Stock Jumps As New Bladder Cancer Guideline Boosts Anktiva Use Benzinga

Roberto Contieri Shares Key Insights on Bladder Cancer Care at EAU 2026 - Oncodaily

Roberto Contieri Shares Key Insights on Bladder Cancer Care at EAU 2026 Oncodaily

Women Leading Change in Bladder Cancer: Addressing Diagnostic Delays and Unique Needs - Jeannie Hoffman-Censits - UroToday

Women Leading Change in Bladder Cancer: Addressing Diagnostic Delays and Unique Needs - Jeannie Hoffman-Censits UroToday

EAU 2026: Nectin4-Targeted Fluorescence Imaging for Enhanced TURBT: From Preclinical Validation to First in Human Application - UroToday

EAU 2026: Nectin4-Targeted Fluorescence Imaging for Enhanced TURBT: From Preclinical Validation to First in Human Application UroToday

Revisiting Radiation for Non-Muscle-Invasive Bladder Cancer - Ananya Choudhury - UroToday

Revisiting Radiation for Non-Muscle-Invasive Bladder Cancer - Ananya Choudhury UroToday

EAU 2026: CORE-008 Cohort B: Evaluating Intravesical Cretostimogene Grenadenorepvec in Patients with High-Risk, BCG-Exposed NMIBC - UroToday

EAU 2026: CORE-008 Cohort B: Evaluating Intravesical Cretostimogene Grenadenorepvec in Patients with High-Risk, BCG-Exposed NMIBC UroToday

EAU 2026: Consistent Efficacy of Durable Response in BCG Relapse, Refractory and Unresponsive Disease in a Pre-Determined Subgroup Analysis of NAI + BCG in BCG-Unresponsive NMIBC CIS +/- Ta/T1 Papillary Disease - UroToday

EAU 2026: Consistent Efficacy of Durable Response in BCG Relapse, Refractory and Unresponsive Disease in a Pre-Determined Subgroup Analysis of NAI + BCG in BCG-Unresponsive NMIBC CIS +/- Ta/T1 Papillary Disease UroToday

EAU 2026: Bladder Preservation Post-neoadjuvant Chemotherapy: A Smart Strategy or Risky Business? - UroToday

EAU 2026: Bladder Preservation Post-neoadjuvant Chemotherapy: A Smart Strategy or Risky Business? UroToday

EAU 2026: ZipUP: 89Zirconium-Labelled Girentuximab PET in Patients with Urothelial Cancer - UroToday

EAU 2026: ZipUP: 89Zirconium-Labelled Girentuximab PET in Patients with Urothelial Cancer UroToday

EAU 2026: Case-Based Panel Discussion High-Risk NMIBC Post-BCG Failure: Spare the Bladder? Bladder Sparing: Trial Overview Intravesical Gene Therapy (Combinations) - UroToday

EAU 2026: Case-Based Panel Discussion High-Risk NMIBC Post-BCG Failure: Spare the Bladder? Bladder Sparing: Trial Overview Intravesical Gene Therapy (Combinations) UroToday

MTAP Loss and Key Alteration Detection via Liquid Biopsy Explored in Bladder Cancer - Chiara Mercinelli - UroToday

MTAP Loss and Key Alteration Detection via Liquid Biopsy Explored in Bladder Cancer - Chiara Mercinelli UroToday

BCAN Unveils Patient-Centered Survey on Emotional and Financial Impacts of Bladder Cancer - Meri-Margaret Deoudes - UroToday

BCAN Unveils Patient-Centered Survey on Emotional and Financial Impacts of Bladder Cancer - Meri-Margaret Deoudes UroToday

EAU 2026: Factors Associated with Inferior Outcomes in Patients with Advanced Urothelial Carcinoma Treated with First-Line Enfortumab Vedotin + Pembrolizumab: Results from UNITE - UroToday

EAU 2026: Factors Associated with Inferior Outcomes in Patients with Advanced Urothelial Carcinoma Treated with First-Line Enfortumab Vedotin + Pembrolizumab: Results from UNITE UroToday

Relmada’s Withdrawn Phase 3 Bladder Cancer Trial: What It Means for RLMD Investors - TipRanks

Relmada’s Withdrawn Phase 3 Bladder Cancer Trial: What It Means for RLMD Investors TipRanks

EAU 2026: Phase 1/2 Study of an Anti-PD-L1/IL-15 Variant Fusion Protein (SIM0237) in BCG Unresponsive High-Risk NMIBC - UroToday

EAU 2026: Phase 1/2 Study of an Anti-PD-L1/IL-15 Variant Fusion Protein (SIM0237) in BCG Unresponsive High-Risk NMIBC UroToday

J&J says Inlexzo follow-up 'promising' in bladder cancer - pharmaphorum

J&J says Inlexzo follow-up 'promising' in bladder cancer pharmaphorum

EAU 2026: State-of-the-Art Lecture BCG-Naïve NMIBC in 2025: Are We Moving Beyond BCG Alone? - UroToday

EAU 2026: State-of-the-Art Lecture BCG-Naïve NMIBC in 2025: Are We Moving Beyond BCG Alone? UroToday

EAU 2026 – J&J strengthens its bladder hand | ApexOnco - Clinical Trials news and analysis - Oncology Pipeline

EAU 2026 – J&J strengthens its bladder hand | ApexOnco - Clinical Trials news and analysis Oncology Pipeline

Genito-Urinary Oncology Summit 2026 - inewsource

Genito-Urinary Oncology Summit 2026 inewsource

NCCN Guideline Expansion Puts ANKTIVA And ImmunityBio Growth In Focus - Yahoo Finance

NCCN Guideline Expansion Puts ANKTIVA And ImmunityBio Growth In Focus Yahoo Finance

Simcere Showcases Promising Bladder Cancer Data for Novel Immunotherapy SIM0237 - TipRanks

Simcere Showcases Promising Bladder Cancer Data for Novel Immunotherapy SIM0237 TipRanks

Phase 1 data support erda-iDRS as bladder-sparing strategy in FGFR-altered disease - Urology Times

Phase 1 data support erda-iDRS as bladder-sparing strategy in FGFR-altered disease Urology Times

Insights from 1,100 Bladder Cancer Patients on Diagnosis and Care – BCAN - Oncodaily

Insights from 1,100 Bladder Cancer Patients on Diagnosis and Care – BCAN Oncodaily

enGene Highlights 2026 Data Catalysts, BLA Plans for Bladder Cancer Gene Therapy at Barclays Conference - Yahoo Finance

enGene Highlights 2026 Data Catalysts, BLA Plans for Bladder Cancer Gene Therapy at Barclays Conference Yahoo Finance

UroGen Applauds BCAN’s New Faces of Bladder Cancer Report Highlighting Recurrence Burden and Fear of Recurrence - Yahoo Finance

UroGen Applauds BCAN’s New Faces of Bladder Cancer Report Highlighting Recurrence Burden and Fear of Recurrence Yahoo Finance

Mayo Clinic expert highlights improved survival in muscle-invasive bladder cancer and kidney cancer - Mayo Clinic News Network

Mayo Clinic expert highlights improved survival in muscle-invasive bladder cancer and kidney cancer Mayo Clinic News Network

Bloody Urine in the ED? Early Imaging May Improve Outcomes - Medscape

Bloody Urine in the ED? Early Imaging May Improve Outcomes Medscape

Five Under 5: Top Oncology Videos for the Week of 3/8 - OncLive

Five Under 5: Top Oncology Videos for the Week of 3/8 OncLive